Kaci Dominguez, PharmD

Letters to the Editor

Atezolizumab Plus Bevacizumab Is Cost-Effective for Advanced HCC When Utilizing Biosimilars

10/20/2021

Aimee Ginsburg, PharmD, BCPS

Leslie Busby, MD

Kaci Dominguez, PharmD

Josh Howell, PharmD, BCOP

Aimee Ginsburg, PharmD, BCPS, and colleagues argue that atezolizumab plus bevacizumab is cost-effective when compared with sorafenib under current pricing, despite contradicting findings from a study presented at ASCO 2021.

Aimee Ginsburg, PharmD, BCPS,...

10/20/2021

Journal of Clinical Pathways

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

September 18 ⁠–⁠ September 20

September 21 ⁠–⁠ September 22

September 30 ⁠–⁠ October 2

October 1 ⁠–⁠ October 2

October 2 ⁠–⁠ October 5

October 5 ⁠–⁠ October 6

October 14 ⁠–⁠ October 16

October 16 ⁠–⁠ October 19

October 19 ⁠–⁠ October 20

October 26 ⁠–⁠ October 27

See Full Calendar

Kaci Dominguez, PharmD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products